Adverse Events Associated with Ethical Kampo Formulations: Analysis of the Domestic Adverse-Event Data Reports of the Ministry of Health, Labor, and Welfare in Japan

Table 1

The number of reported adverse events associated with ethical Kampo formulations per fiscal year by category.

FY	Liver	Lung	PA	MP	Drug	Others	Total
	injury	injury			eruption
	42	27	13	0	8	31	121
	55	25	26	0	8	18	132
2005	81	54	29	0	6	9	179
2006	80	52	58	1	8	15	214
2007	60	42	49	1	10	32	194
	61	41	51	2	10	22	187
	80	68	58	3	17	28	254
2010	75	65	65	13	15	21	254
2011	88	105	48	11	8	22	282
2012	83	105	56	15	11	39	309
2013	80	82	50	41	11	28	292
2014	72	108	48	27	13	23	291
2015	76	84	89	37	10	22	318
2016	142	169	98	34	23	98	564
2017	118	150	151	38	27	157	641
Total	1,193	1,177	889	223	185	565	4,232

FY: Fiscal year until the end of March of the following year; MP: Mesenteric phlebosclerosis; PA: Pseudoaldosteronism.
for approximately 8 months, from July 30, 2003 to March 31, 2004.
for 8 months, from August 1, 2004 to March 31, 2005. Data from April 1, 2004 to June 30, 2004 are missing.
for 11 months, from April 1, 2008 to February 28, 2009.
for 13 months, from March 1, 2009 to March 31, 2010.